Neuren Pharmaceuticals Limited (NURPF) Financial Metrics
This dashboard provides comprehensive financial metrics and analysis to help evaluate Neuren Pharmaceuticals Limited's investment potential. View key valuation ratios, profitability metrics, growth indicators, and historical trends to make informed investment decisions.
Financial Metrics Score
Valuation Metrics
Sector benchmarks: Industrials
P/E Ratio
77.54
Weak
WeakModerateStrong
P/B Ratio
7.05
Weak
WeakModerateStrong
Earnings Yield
1.28%
Yield Trap
WeakModerateStrong
Profitability Health
2025Return on Equity
8.99%
Weak
WeakModerateStrong
Operating Margin
34.07%
Strong
WeakModerateStrong
Net Profit Margin
47.09%
Strong
WeakModerateStrong
Growth Indicators
2025Revenue Growth
-70.20%
Weak
WeakModerateStrong
Net Income Growth
-78.58%
Weak
WeakModerateStrong
EPS Growth
-77.98%
Weak
WeakModerateStrong
Efficiency & Liquidity
2025Current Ratio
76.60
Strong
WeakModerateStrong
Quick Ratio
76.60
Strong
WeakModerateStrong
Asset Turnover
0.19x
Weak
WeakModerateStrong
Inventory Turnover
-
No data
Cash Flow & Resilience
Core fortress metrics for cash-rich balance sheets in high-inflation / tech-volatility regimes
Free Cash Flow Yield
5.25%
Strong
WeakModerateStrong
EV / Free Cash Flow
19.00x
Strong
WeakModerateStrong
Net Debt / EBITDA
-0.19x
Strong
WeakModerateStrong
Interest Burden (EBT / EBIT)
1.768
Strong
WeakModerateStrong
Return on Invested Capital
5.09%
Weak
WeakModerateStrong
Cash Conversion Cycle
-13767.72 days
Strong
WeakModerateStrong
Fortress screener guardrails
3/4 passing
- FCF Yield > 3%
- Net Debt / EBITDA < 1.5x
- ROIC > 20%
- Cash Conversion Cycle < 0 days
Financial Statements
Want to see the complete financial picture? View detailed financial statements including income statements, balance sheets, and cash flow statements for NURPF.
View Financial Statements